X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1212) 1212
Newsletter (101) 101
Publication (95) 95
Book Review (17) 17
Conference Proceeding (2) 2
Dissertation (2) 2
Magazine Article (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gemfibrozil (867) 867
humans (662) 662
pharmacology & pharmacy (544) 544
male (471) 471
gemfibrozil - pharmacology (379) 379
animals (323) 323
index medicus (270) 270
hypolipidemic agents - pharmacology (267) 267
female (258) 258
middle aged (212) 212
adult (206) 206
drug interactions (196) 196
rats (179) 179
metabolism (161) 161
hypolipidemic agents - therapeutic use (138) 138
gemfibrozil - therapeutic use (136) 136
cholesterol (133) 133
fibric acids (127) 127
pharmacokinetics (127) 127
aged (121) 121
triglycerides - blood (118) 118
fenofibrate (98) 98
hyperlipidemias - drug therapy (98) 98
mice (91) 91
plasma-concentrations (91) 91
biochemistry & molecular biology (90) 90
coronary-heart-disease (88) 88
liver - drug effects (83) 83
atherosclerosis (82) 82
cholesterol - blood (81) 81
fenofibrate - pharmacology (81) 81
cholesterol, hdl - blood (80) 80
research (78) 78
simvastatin (76) 76
bezafibrate - pharmacology (74) 74
toxicology (73) 73
liver - metabolism (72) 72
cerivastatin (71) 71
drugs (71) 71
rhabdomyolysis (71) 71
statins (71) 71
cross-over studies (70) 70
coronary heart-disease (69) 69
dose-response relationship, drug (69) 69
fibrates (69) 69
pharmacology/toxicology (69) 69
risk factors (69) 69
liver (68) 68
area under curve (67) 67
in-vitro (67) 67
rats, sprague-dawley (67) 67
lipids (66) 66
men (65) 65
reports (64) 64
lipids - blood (63) 63
cytochrome p-450 (62) 62
hypolipidemic agents - adverse effects (62) 62
gemfibrozil - pharmacokinetics (60) 60
plasma (60) 60
drug-interactions (59) 59
atorvastatin (57) 57
cells, cultured (57) 57
lovastatin (57) 57
medicine & public health (57) 57
cardiac & cardiovascular systems (56) 56
pravastatin (56) 56
clofibric acid - pharmacology (55) 55
gemfibrozil - adverse effects (55) 55
gemfibrozil - administration & dosage (54) 54
chemistry, medicinal (53) 53
peripheral vascular disease (53) 53
pharmacology (53) 53
therapy (53) 53
analysis (52) 52
physiological aspects (52) 52
cholesterol, ldl - blood (51) 51
cyp2c8 (51) 51
drug therapy, combination (51) 51
hypertriglyceridemia (51) 51
prevention (51) 51
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (50) 50
inhibition (50) 50
kinetics (50) 50
time factors (50) 50
triglycerides (50) 50
fenofibrate - therapeutic use (49) 49
hyperlipidemia (49) 49
rats, wistar (49) 49
bezafibrate (48) 48
dyslipidemia (48) 48
medicine, research & experimental (48) 48
risk (48) 48
universities and colleges (48) 48
clofibrate - pharmacology (46) 46
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (46) 46
microsomes, liver - drug effects (46) 46
double-blind method (44) 44
lipoproteins - blood (44) 44
cytochrome p-450 cyp2c8 (43) 43
hypolipidemic agents - pharmacokinetics (43) 43
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1301) 1301
French (7) 7
German (5) 5
Russian (3) 3
Japanese (2) 2
Chinese (1) 1
Croatian (1) 1
Hungarian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1308 - 1314
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic... 
RAT | SEVERE RHABDOMYOLYSIS | COMBINATION THERAPY | LIVER | PHARMACOLOGY & PHARMACY | CERIVASTATIN | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | ROSUVASTATIN | POLYPEPTIDE | FAMILY | Organic Anion Transporters, Sodium-Independent - genetics | Fatty Acids, Monounsaturated - pharmacology | Cricetulus | Hypolipidemic Agents - metabolism | Hypoglycemic Agents - metabolism | Taurocholic Acid - metabolism | Humans | Hepatocytes - metabolism | Simvastatin - pharmacology | Organic Anion Transporters - metabolism | Chromans - metabolism | Hepatocytes - cytology | Indoles - metabolism | Organic Anion Transporters - genetics | Drug Interactions | Anticholesteremic Agents - metabolism | Chromans - pharmacology | Fatty Acids, Monounsaturated - metabolism | Organic Anion Transporters, Sodium-Independent - metabolism | Indoles - pharmacology | Biological Transport - drug effects | Thiazolidinediones - pharmacology | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Pravastatin - pharmacology | Recombinant Proteins - metabolism | Taurocholic Acid - pharmacology | Cell Line | Cricetinae | Pravastatin - metabolism | Simvastatin - metabolism | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Thiazolidinediones - metabolism | Hypoglycemic Agents - pharmacology | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Protein Binding | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Kinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Anticholesteremic Agents - pharmacology | Gemfibrozil - metabolism
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 4/2013, Volume 30, Issue 4, pp. 1188 - 1199
Quantitative prediction of complex drug-drug interactions (DDIs) is challenging. Repaglinide is mainly metabolized by cytochrome-P-450 (CYP)2C8 and CYP3A4, and... 
Biochemistry, general | Biomedical Engineering | repaglinide | CYP2C8 | Biomedicine | physiologically-based pharmacokinetic model | Pharmacy | Medical Law | Pharmacology/Toxicology | gemfibrozil | drug-drug interaction | OATP1B1 | GLUCURONIDE INHIBIT | IN-VITRO CLEARANCE | METABOLIC PATHWAYS | HUMAN LIVER-MICROSOMES | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | INHIBITION MECHANISMS | SANDWICH CULTURE | PLASMA-CONCENTRATIONS | TISSUE DISTRIBUTION | PHARMACOLOGY & PHARMACY | Cytochrome P-450 CYP2C8 | Humans | Hepatocytes - metabolism | Carbamates - pharmacokinetics | Organic Anion Transporters - metabolism | Drug Interactions | Piperidines - pharmacology | Piperidines - pharmacokinetics | Hypolipidemic Agents - chemistry | Hepatocytes - drug effects | Carbamates - pharmacology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Hypoglycemic Agents - pharmacokinetics | Organic Anion Transporters - antagonists & inhibitors | Biological Transport, Active - drug effects | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Hypoglycemic Agents - pharmacology | Models, Biological | Gemfibrozil - analogs & derivatives | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Side effects | Pharmacology | Liver | Pharmaceuticals
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 8/2018, Volume 74, Issue 8, pp. 1021 - 1028
On account of the potential inhibition of OATP1B1 (organic anion transporting polypeptide) by angiotensin II receptor blockers (ARBs) and the effects of... 
SLCO1B1 | Pharmacodynamics | Biomedicine | Irbesartan | Drug interactions | Repaglinide | Pharmacology/Toxicology | Pharmacokinetics | Polymorphism | GEMFIBROZIL | OATP1B1 OATP-C | GENETIC POLYMORPHISMS | PITAVASTATIN | MAJOR DETERMINANT | HEPATIC-UPTAKE | TRANSPORTING POLYPEPTIDE 1B1 | IN-VITRO | CYP2C8 | PHARMACOLOGY & PHARMACY | SINGLE NUCLEOTIDE POLYMORPHISMS | Tetrazoles - pharmacology | Humans | Asian Continental Ancestry Group - genetics | Male | Healthy Volunteers | Carbamates - pharmacokinetics | Piperidines - blood | Valsartan - pharmacology | Dose-Response Relationship, Drug | Young Adult | Drug Interactions - genetics | Biphenyl Compounds - pharmacology | Piperidines - pharmacology | Adult | Piperidines - pharmacokinetics | Carbamates - pharmacology | Solute Carrier Organic Anion Transporter Family Member 1b1 - genetics | China - ethnology | Cells, Cultured | Losartan - pharmacology | Carbamates - blood | Genotype | Imidazoles - pharmacology | Blood Glucose - drug effects | Solute Carrier Organic Anion Transporter Family Member 1b1 - antagonists & inhibitors | Polymorphism, Single Nucleotide - genetics | Complications and side effects | Pharmacogenetics | Analysis | Angiotensin | Exposure | Pharmacology | Gene polymorphism | Blood levels | Organic anion transporting polypeptide | Genotype & phenotype | Anions | Drug interaction | Angiotensin II | In vitro methods and tests | Transporter | Genotypes
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2015, Volume 55, Issue 4, pp. 392 - 400
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 2/2012, Volume 29, Issue 2, pp. 411 - 426
To establish in vitro and in silico models that predict clinical drug–drug interactions (DDIs) with the OATP1B1 (SLCO1B1) transporter.The inhibitory effect of... 
Biomedical Engineering | Biochemistry, general | Biomedicine | MRP2 | Pharmacy | Medical Law | inhibition | in silico | Pharmacology/Toxicology | in vitro – in vivo extrapolation | OATP1B1 | In silico | Inhibition | In vitro-in vivo extrapolation | HEALTHY-SUBJECTS | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | ANION TRANSPORTING POLYPEPTIDE | CYCLOSPORINE-A | PHARMACOKINETICS | in vitro-in vivo extrapolation | PLASMA-CONCENTRATIONS | LIVER | PHARMACOLOGY & PHARMACY | ROSUVASTATIN | Estradiol - analogs & derivatives | Gene Expression | Organic Anion Transporters - antagonists & inhibitors | Humans | Organic Anion Transporters - metabolism | Atorvastatin Calcium | Pyrroles - pharmacology | Drug Interactions | Models, Biological | Computer Simulation | HEK293 Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Estradiol - pharmacology | Heptanoic Acids - pharmacology | Complications and side effects | Antiviral agents | Cyclosporine | Gemfibrozil | Drug interactions | Fibric acids | Clinical trials | Models | Inhibitor drugs | in vitro–in vivo extrapolation | Research Paper | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Galenisk farmaci | Pharmaceutics | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Biopharmaceutics | Medicinska och farmaceutiska grundvetenskaper | Biopharmacy | FARMACI | Biofarmaci
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article